Noramco and SPI Pharma have signed an agreement to develop and license a set of “value-added” formulation packages for global pharmaceutical manufacturers of finished dosage forms.    The agreement will focus on finished dosage products for licensing to customers through dossiers developed by SPI Pharma for implementation by generic and branded pharmaceutical companies.  Neither Noramco nor SPI has any intention to produce or market finished dosage forms.     “Bringing together N...